Lilly's Solanezumab Picked for Alzheimer Prevention Study
Despite the fact that Lilly's solanezumab failed in recent phase 3 trials (and despite vigorous attempts to pound out convincing clinical and biomarker data), the anti-amyloid MAb will be assessed in an upcoming prevention study in at-risk, nondemented elderly. The compound was likely selected over another failed anti-amyloid MAb, bapineuzumab, on the basis of more favorable safety data.
Notably the subjects for the new government-funded prevention trial will demonstrate amyloid build-up on brain images. In the phase 3 solanezumab trials, a substantial percentage of enrollees (~20%) did not demonstrate excessive amyloid on PET brain images—making the interpretation of biomarker results problematic.
MAb = monoclonal antibody; PET = positron emission tomography.
Notably the subjects for the new government-funded prevention trial will demonstrate amyloid build-up on brain images. In the phase 3 solanezumab trials, a substantial percentage of enrollees (~20%) did not demonstrate excessive amyloid on PET brain images—making the interpretation of biomarker results problematic.
MAb = monoclonal antibody; PET = positron emission tomography.
